Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Stefan Foser"'
Autor:
Rekha Badiger, Jane A Mitchell, Hime Gashaw, Neil A Galloway-Phillipps, Stefan Foser, Fernando Tatsch, Thomas Singer, Trevor T Hansel, Tobias Manigold
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e46779 (2012)
Alfa-interferons (IFNα2a, IFNα2b, 40KDa-PEGIFNα2a and 12KDa-PEGIFNα2b) are effective treatments for chronic hepatitis C infection. However, their usage has been associated with a variety of adverse events, including interstitial pneumonitis and p
Externí odkaz:
https://doaj.org/article/8b3d9158413b4a5190c0cfc5b2c0d180
Autor:
Georgios Pentheroudakis, Stefan Foser, George Zarkavelis, Tilmann Bochtler, Andreas Beringer, Mustafa Ozguroglu, Chantal Pauli, Ferran Losa, M. Mueller-Ohldach, Alwin Krämer, J.S. Ross, J. Scarato, Holger Moch, Giulia Baciarello, Linda Mileshkin, S Songül Yalçin
Publikováno v:
Publons
Background The CUPISCO trial (NCT03498521) is an ongoing, phase II, randomised, multicentre study comparing molecularly-guided therapy with standard platinum-based chemotherapy in newly diagnosed poor-risk CUP patients. Methods Eligible patients have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae3006d9ea1285496d70beb1988d36d
https://doi.org/10.1093/annonc/mdz269.054
https://doi.org/10.1093/annonc/mdz269.054
Autor:
Stefan Foser, C. Mascaux, Kieran Mace, James W. Clendening, Lisa I. Wang, Luis Paz-Ares, Lukas Bubendorf, Q. Zhang, Adam Gondos, Fabrice Barlesi
Publikováno v:
Journal of Clinical Oncology. 37:9076-9076
9076 Background: The number of targeted txs for NSCLC is increasing. By analyzing numerous molecular alterations, CGP may open more targeted tx options than single biomarker testing. Methods: We analyzed a database linking Flatiron Health electronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b2917a5a60a26800c201d46b001283b
https://doi.org/10.1200/jco.2019.37.15_suppl.9076
https://doi.org/10.1200/jco.2019.37.15_suppl.9076
Autor:
Alwin Krämer, Ferran Losa, Laurie M. Gay, Ethan Sokol, Damian R. Page, Garrett Michael Frampton, Stefan Foser, Tariq I. Mughal, Jeffrey S. Ross, Giulia Baciarello, Linda R. Mileshkin, Holger Moch
Publikováno v:
Journal of Clinical Oncology. 36:e24162-e24162
e24162Background: CUP represents a wide range of heterogeneous tumors with diverse genomic alterations (GAs) and high unmet clinical need. Molecular profiling of gene panels at diagnosis is increas...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f91f026d168371d441806293f7d4d68
https://doi.org/10.1200/jco.2018.36.15_suppl.e24162
https://doi.org/10.1200/jco.2018.36.15_suppl.e24162
Autor:
Francis Müller, Alfred Ross, Stefan Foser, Luc-Alexis Leuthold, Hans Martin Senn, Bernard Gsell, Christophe Dhalluin
Publikováno v:
Bioconjugate Chemistry. 16:504-517
The human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) to treat various types of cancer and viral diseases including Hepatitis B/C infections. To improve the pharmacological properties of the drug, a new pegylated form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aea0008a5483c2954a61275444e0cc62
https://doi.org/10.1021/bc049781+
https://doi.org/10.1021/bc049781+
Publikováno v:
Thrombosis and Haemostasis. 94:347-361
SummaryThe bacterial pathogen Bartonella henselae (Bh) is for respona sible broad range of clinical manifestations, including the formation of vascular tumours as the result of pathogen-triggered vasoproliferation. In vitro, the interaction of Bh wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5bebf1a5df9b5f212f68a6c8d76aff0
https://doi.org/10.1160/th05-02-0106
https://doi.org/10.1160/th05-02-0106
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 31(8)
The interferon (IFN)-α response gene interferon-induced transmembrane protein 3 (IFITM3) has antiproliferative properties in a number of biological systems. In the human melanoma cell line D10, IFITM3 is constitutively expressed and we show that the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43147b2c5ce944f1da147578603e2098
https://pubmed.ncbi.nlm.nih.gov/21413873
https://pubmed.ncbi.nlm.nih.gov/21413873
Autor:
Martin Ebeling, Bernd Bohrmann, Y. Burki, L.C. Hallen, C. Broger, Krisztina Oroszlan-Szovik, Fredy Siegrist, Ulrich Certa, Stefan Foser
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 27(8)
The interferon-alpha (IFN-alpha)-inducible protein IFI44 is associated with hepatitis C virus (HCV) infection, and its function is unknown. We show here in two human melanoma cell lines (ME15 and D10) that transcription starts 4 h after induction, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ce39a935531af7ed4670c49af9dc01
https://pubmed.ncbi.nlm.nih.gov/17784819
https://pubmed.ncbi.nlm.nih.gov/17784819
Autor:
Christophe, Dhalluin, Alfred, Ross, Luc-Alexis, Leuthold, Stefan, Foser, Bernard, Gsell, Francis, Müller, Hans, Senn
Publikováno v:
Bioconjugate chemistry. 16(3)
The human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) to treat various types of cancer and viral diseases including Hepatitis B/C infections. To improve the pharmacological properties of the drug, a new pegylated form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc9da757d4d97e11aa1fd96bde4d7e66
https://pubmed.ncbi.nlm.nih.gov/15898716
https://pubmed.ncbi.nlm.nih.gov/15898716
Publikováno v:
The pharmacogenomics journal. 3(6)
The addition of polyethyleneglycol (PEG) side chains to interferon alpha-2a improves the serum stability and clinical efficacy. Current commercial PEG-INF formulations such as PEGASYS are heterogeneous and contain multiple monopegylated isomers. We h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b178854061e45c1e3ee0b69ce1979b
https://pubmed.ncbi.nlm.nih.gov/14569259
https://pubmed.ncbi.nlm.nih.gov/14569259